STOCK TITAN
  1. Home
  2. News
  3. CORT

Corcept Therapeutics Inc - CORT STOCK NEWS

Welcome to our dedicated news page for Corcept Therapeutics (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Corcept Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Corcept Therapeutics's position in the market.

News
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
Rhea-AI Summary
Corcept Therapeutics (NASDAQ: CORT) will unveil its first quarter financial results and share a corporate update on May 1, 2024. A conference call is scheduled for 5:00 p.m. Eastern Time. Participants need to register in advance to receive the dial-in number and access PIN.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
Rhea-AI Summary
Corcept Therapeutics announces positive results from the open-label portion of the pivotal Phase 3 GRACE trial for relacorilant in patients with Cushing’s syndrome. The trial showed significant improvements in hypertension, hyperglycemia, and other key endpoints without adverse effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
clinical trial
-
News
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
Rhea-AI Summary
Corcept Therapeutics Incorporated completes enrollment in Phase 2 DAZALS trial for ALS patients, testing dazucorilant's efficacy in improving motor performance and quality of life. The study enrolled 249 patients and is expected to provide data by the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
clinical trial
News
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
Rhea-AI Summary
Corcept Therapeutics (CORT) completes enrollment in ROSELLA Phase 3 trial for ovarian cancer treatment with relacorilant and nab-paclitaxel, aiming to improve patient outcomes. The trial mirrors positive Phase 2 results, showing potential for relacorilant to enhance survival rates. Progression-free survival data expected by year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
clinical trial
-
News
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
Rhea-AI Summary
Corcept Therapeutics (CORT) completes enrollment in Phase 3 trial for relacorilant in patients with Cushing’s syndrome, targeting serious cardiometabolic comorbidities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
clinical trial
-
News
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
Rhea-AI Summary
Corcept Therapeutics Incorporated (CORT) reported strong financial results for Q4 2023 and full year 2023, with revenue increases of 31% and 20% respectively. They reiterated revenue guidance for 2024 at $600 - $630 million. The company's net income also showed significant growth. Clinical development programs are progressing well, with key milestones expected this year. Corcept is on-track to submit an NDA for relacorilant in Cushing’s syndrome and report data from various trials in Cushing’s syndrome, ovarian cancer, ALS, and more.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.15%
Tags
earnings
News
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
Rhea-AI Summary
Corcept Therapeutics (CORT) announces preliminary results from the prevalence phase of its CATALYST study on Cushing’s syndrome in patients with difficult-to-control type 2 diabetes. The study, with 1,000 patients, reveals a 24% prevalence rate of hypercortisolism, higher than previously assumed. Final results to be presented at the American Diabetes Association’s 84th Scientific Sessions in June.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.15%
Tags
clinical trial
-
News
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
Rhea-AI Summary
Corcept Therapeutics Incorporated (NASDAQ: CORT) will report Q4 and full-year 2023 financial results and provide a corporate update on February 15, 2024. A conference call is scheduled at 5:00 p.m. Eastern Time. Participants must register in advance to receive dial-in number and access PIN. A listen-only webcast and call replay will also be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
earnings
-
News
Corcept Appoints Roberto Vieira as President, Oncology
Rhea-AI Summary
Corcept Therapeutics Incorporated (NASDAQ: CORT) has appointed Roberto Vieira as President, Oncology. Vieira brings extensive experience in global commercialization of cancer medicines and building high-performing teams. He aims to lead Corcept's oncology division, initially focusing on ovarian cancer and expanding to other tumors, with a commitment to revolutionize cancer treatment through cortisol modulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
management
News
Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
Rhea-AI Summary
Corcept Therapeutics Incorporated (CORT) reported preliminary, unaudited, financial results for the quarter- and year-ended December 31, 2023, provided 2024 revenue guidance, and announced a stock repurchase program. Fourth quarter revenue increased by 31% to $135.4 million, and full year 2023 revenue increased by 20% to $482.4 million. The company also announced a 2024 revenue guidance of $600 – $630 million and a $200 million stock repurchase program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.1%
Tags
buyback
Stock CORT logo
Corcept Therapeutics Inc

Nasdaq:CORT

CORT Rankings

#1762 Ranked by Market Cap
#2284 Ranked by Stock Gains
N/A Ranked by Dividends

CORT Stock Data

2.44B
84.92M
11.41%
83.63%
20.61%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Menlo Park

About CORT

leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis